Article
Biochemistry & Molecular Biology
Felix Pham, Samy Belkaid, Denis Maillet, Cyrille B. Confavreux, Stephane Dalle, Julien Peron
Summary: The presence of baseline bone metastases appears to be associated with worse outcomes in RCC combo-ICI-treated patients, while its effect may not be independent from the inflammatory state. However, bone metastases seem to have no impact on the outcomes of melanoma combo-ICI-treated patients.
Letter
Oncology
Wee Loon Ong, Shankar Siva, Roger L. Milne, Farshad Foroudi, Jeremy L. Millar
Summary: This letter to the editor adds to the limited literature on the trend in the use of stereotactic radiation therapy for metastatic renal cell carcinoma.
Article
Endocrinology & Metabolism
Margaret Zacharin, Angelina Lim, James Gryllakis, Aris Siafarikas, Craig Jefferies, Julie Briody, Natasha Heather, Janne Pitkin, Jaiman Emmanuel, Katherine J. Lee, Xiaofang Wang, Peter J. Simm, Craig F. Munns
Summary: The study found that using zoledronic acid in DMD patients significantly improved bone mineral density. Compared to the control group, the ZA group had a significantly higher LS BMD Z-score difference at 12 and 24 months, with no impact on pain, mobility, and bone turnover. Additionally, the ZA group showed improvements in pQCT measurements compared to the control group.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Oncology
Jianpo Zhai, Ning Liu, Hai Wang, Guanglin Huang, Libo Man
Summary: This study aimed to define the clinical characteristics and prognostic factors of RCC with spinal bone metastasis (sBM). The analysis found that MSKCC risk stratification, number of sBM, visceral metastasis, and en-block resection are significant prognostic factors for overall survival in RCC patients with spinal BM. For selected patients with solitary spinal BM and no visceral metastasis, en-block resection of spinal BM may potentially prolong survival and is the treatment of choice.
FRONTIERS IN ONCOLOGY
(2021)
Editorial Material
Medicine, General & Internal
Katarzyna Romejko, Adam Rytel, Tomasz Rozmyslowicz, Stanislaw Niemczyk
Summary: Renal cell carcinoma (RCC) is a common genitourinary cancer, with clear cell renal cell carcinoma (ccRCC) being the most common histologic type. The incidence of ccRCC diagnosis has rapidly increased due to the development of imaging methods. However, a significant proportion of patients are already at metastatic stage at the time of diagnosis, with metastases commonly found in the lungs, bones, and liver. Metastasis of ccRCC to the heart is rare, and we present a rare case of ccRCC with heart tissue metastases visualized in transthoracic echocardiography.
Article
Dentistry, Oral Surgery & Medicine
Dan Zhao, Dexuan Xiao, Mengting Liu, Jiajie Li, Shuanglin Peng, Qing He, Yue Sun, Jingang Xiao, Yunfeng Lin
Summary: In this study, a novel nanoparticle tFNA-KLT was synthesized and shown to effectively prevent the occurrence of BRONJ by accelerating angiogenesis.
INTERNATIONAL JOURNAL OF ORAL SCIENCE
(2022)
Article
Multidisciplinary Sciences
Pei-An Fu, Chin-Yao Shen, Shuen-Ru Yang, Chun-Hui Lee, Hui-Wen Chen, Edward Chia-Cheng Lai, Wei-Pang Chung
Summary: Denosumab reduces skeletal-related events (SREs) in breast cancer patients with bone metastases, but its long-term efficacy and safety are limited by lack of real-world data. This retrospective study on 132 denosumab-treated patients found that 11.1% experienced SREs in the first year, with the rate increasing over time. Additionally, 7.6% developed osteonecrosis of the jaw (ONJ), but most of those who resumed denosumab did not experience recurrence of ONJ.
SCIENTIFIC REPORTS
(2023)
Review
Biochemistry & Molecular Biology
Franz Sellner, Eva Comperat, Martin Klimpfinger
Summary: Isolated pancreatic metastases of renal cell carcinoma (IsPMRCC) is a rare manifestation of metastatic renal cell carcinoma, and it has unique clinical characteristics such as delayed metastasis, multiple metastases, favorable treatment outcomes, and insensitivity to risk factors associated with volume and growth rate in metastatic surgery.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Carolin Sauter-Meyerhoff, Regina Bohnert, Pascale Mazzola, Viktoria Stuehler, Siarhei Kandabarau, Florian A. Buettner, Stefan Winter, Lisa Herrmann, Steffen Rausch, Joerg Hennenlotter, Falko Fend, Marcus Scharpf, Arnulf Stenzl, Stephan Ossowski, Jens Bedke, Matthias Schwab, Elke Schaeffeler
Summary: Metastatic renal cell carcinoma (RCC) has poor prognosis, and understanding the genetic landscape of distant metastases is crucial for personalized treatment strategies. The somatic mutational composition is significantly associated with cancer-specific survival, and recurrent metastases show higher mutational burden. Synchronous and/or recurrent metastases of individual patients share a high proportion of somatic events even after a time-period >2 yrs, highlighting the importance of somatic profiling for precision medicine in RCC.
Article
Oncology
Christopher Li, Meghan R. Flanagan, Mei-Tzu C. Tang, Peggy L. Porter, Kathleen E. Malone
Summary: This study demonstrates that bisphosphonate use is associated with a lower risk of subsequent invasive breast cancer among women with a history of DCIS, suggesting a potential preventative approach for this high-risk population.
Article
Rheumatology
Guoqi Cai, Laura L. Laslett, Michael A. Bowes, Philip G. Conaghan, Flavia Cicuttini, Anita E. Wluka, Lyn March, Catherine Hill, Tania Winzenberg, Graeme Jones, Dawn Aitken
Summary: This study evaluated the effect of annual infusions of zoledronic acid with or without methylprednisolone on bone area and bone shape in knee osteoarthritis patients. The results showed that zoledronic acid combined with methylprednisolone can slow down the expansion of bone area, but zoledronic acid alone may not have the same effect. However, neither zoledronic acid with or without methylprednisolone slowed the progression of bone shape.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Oncology
Elshad Hasanov, Debra Nana Yeboa, Mathew D. Tucker, Todd A. Swanson, Thomas Hendrix Beckham, Brian Rini, Chibawanye I. Ene, Merve Hasanov, Sophie Derks, Marion Smits, Shaan Dudani, Daniel Y. C. Heng, Priscilla K. Brastianos, Axel Bex, Sahin Hanalioglu, Jeffrey S. Weinberg, Laure Hirsch, Maria I. Carlo, Ayal Aizer, Paul David Brown, Mehmet Asim Bilen, Eric Lin Chang, Jerry Jaboin, James Brugarolas, Toni K. Choueiri, Michael B. Atkins, Bradley A. McGregor, Lia M. Halasz, Toral R. Patel, Scott G. Soltys, David F. McDermott, James Bradley Elder, Mustafa K. Baskaya, James B. Yu, Robert Timmerman, Michelle Miran Kim, Melike Mut, James Markert, Kathryn Beal, Nizar M. Tannir, George Samandouras, Frederick F. Lang, Rachel Giles, Eric Jonasch
Summary: Brain metastases are a challenging manifestation of renal cell carcinoma, and the optimal treatment approach remains unclear. This study aimed to improve patient care by establishing algorithms for the management of brain metastases through literature review and expert surveys.
CA-A CANCER JOURNAL FOR CLINICIANS
(2022)
Article
Oncology
Maud Velev, Cecile Dalban, Christine Chevreau, Gwenaelle Gravis, Sylvie Negrier, Brigitte Laguerre, Marine Gross-Goupil, Sylvain Ladoire, Delphine Borchiellini, Lionnel Geoffrois, Florence Joly, Frank Priou, Philippe Barthelemy, Mathieu Laramas, Berangere Narciso, Antoine Thiery-Vuillemin, Jean-Francois Berdah, Victoria Ferrari, Quentin Dominique Thomas, Cecile Mione, Hubert Curcio, Stephane Oudard, Florence Tantot, Bernard Escudier, Sylvie Chabaud, Laurence Albiges, Constance Thibault
Summary: This study aimed to assess the impact of bone metastases (BM) on prognosis and the efficacy and safety of nivolumab in renal cell carcinoma (RCC) patients. The results showed that patients with BM had shorter overall survival, lower progression-free survival, and objective response rate when treated with nivolumab. Additionally, the combined use of bone-targeting agents and immunotherapy reduced the incidence of skeletal-related events.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M. Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Marie C. Semira, Peter Gibbs, Ben Tran, Carmel Pezaro
Summary: Bone metastases and SSEs are common in CRPC patients, yet less than half of patients receive BMAs. The use of BMAs in treatment is associated with a lower rate of SSE occurrence.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Margherita Puppo, Manoj Kumar Valluru, Martine Croset, Davide Ceresa, Michele Iuliani, Ashrin Khan, Julien Wicinski, EmmACTanuelle Charafe-Jauffret, Christophe Ginestier, Francesco Pantano, Penelope Dawn Ottewell, Philippe Clezardin
Summary: The study found that microRNA-662 (miR-662) plays a crucial role in the progression of bone metastasis in breast cancer. It suggests that miR-662 could serve as a prognostic marker to identify breast cancer patients at high risk of metastasis.
BRITISH JOURNAL OF CANCER
(2023)
